

Exhibit 2

US Multiple Sclerosis Market

Uniform, Massive Price Inflation

\$AWP

<u>Drug/Manufacturer/Launch Yr</u>	<u>US Annual Cost Per Patient (\$AWP)</u>					
	<u>2006</u>	<u>2010</u>	<u>2013</u>	<u>2015</u>	<u>2017</u>	<u>2018</u>
Avonex (Biogen, 1996)	\$20,066	\$41,587	\$65,448	\$79,834	\$90,533	\$97,775
Pledigry (Biogen, 2014)	-	-	-	79,834	90,533	97,775
Rebif (Pfizer/Serono, 2002)	22,221	37,465	69,644	82,940	98,992	98,992
Betaseron (Bayer, 1993)	20,012	41,311	64,541	81,330	95,728	102,334
Extavia (Novartis, 2009)	=	<u>38,250</u>	<u>57,794</u>	<u>72,694</u>	<u>85,644</u>	<u>90,783</u>
Average Interferon	\$20,766	\$39,653	\$64,357	\$79,326	\$92,286	\$97,532
Copaxone 20 mg (Teva, 1996)	-	\$44,166	\$67,226	\$89,213	\$103,864	\$103,864
Copaxone 40 mg (Teva, 2014)	-	-	-	72,115	83,981	83,981
Glatopa (Sandoz, 2015)	=	=	=	<u>78,991</u>	<u>78,991</u>	<u>78,991</u>
Average Glatiramer		\$44,166	\$67,226	\$80,106	\$88,945	\$88,945
Gilenya (Novartis, 2010)	-	\$56,909	\$71,514	\$89,008	\$106,738	\$113,142
Tecfidera (Biogen, 2013)	-	-	64,800	83,347	98,208	106,064
Aubagio (Sanofi, 2012)	=	=	<u>64,505</u>	<u>83,051</u>	<u>95,209</u>	<u>95,209</u>
Average Oral MS		\$56,909	\$66,940	\$85,135	\$100,051	\$104,805
Average US MS Drug (\$)	\$20,766	\$41,910	\$66,174	\$81,523	\$93,761	\$97,094

Source: Truven/Red Book.

From the District of Rhode Island Whistleblower Complaint filed on August 17, 2018.